Search the Newsreel

Verastem Inc (VSTM) Valuation: PE, PB & Fair Value Analysis

Verastem Inc (VSTM) currently holds a valuation score of 6.10, placing it in the lower quartile of the Biotechnology & Medical Research industry. Its P/E ratio is -2.51, representing a significant drop from its recent high and a moderate increase from its recent low. …

Price to book forward of Erasca, Inc. – NASDAQ:ERAS

This article provides the "Price to book forward" financial metric for Erasca, Inc. (NASDAQ: ERAS). It appears to be a stub or data-focused entry from a financial platform, showing the company's ticker, exchange, and the specific financial value along with its change over a …

Peraso Inc. (PRSO) Q1 2026 Earnings: Slight EPS Miss Goes Unpunished as Shares Gain 3.16% - Geographic Revenue Trends

Peraso Inc. (PRSO) Q1 2026 Earnings: Slight EPS Miss Goes Unpunished as Shares Gain 3.16% - Forward EPS Estimate

AUGUST 10, 2026 INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for purchasers of its common stock between January 14, 2025, and April 26, 2026. Investors who suffered substantial losses are encouraged to seek appointment as lead plaintiff …

Form PRE 14A Peraso Inc For: 29 July By Investing.com

This article reports that Peraso Inc. filed a Form PRE 14A on July 29th. The filing is available through Investing.com, a financial markets platform. The brief piece includes a stock performance indicator for PRSO, showing a 0.78% increase.

Jerash Holdings to Report Financial Results for Fiscal 2027 First Quarter on Monday, August 10, 2026

Jerash Holdings (US), Inc. (NASDAQ:JRSH) announced it will release its financial results for the fiscal 2027 first quarter, ending June 30, 2026, on Monday, August 10, 2026, before the market opens. The company will also host an investor conference call on the same day …

Jerash Holdings schedules fiscal update and webcast for Aug. 10

Jerash Holdings (NASDAQ: JRSH) will release its fiscal 2027 first-quarter results before market open on Monday, August 10, 2026. The company will host an investor conference call at 9:00 a.m. ET on the same day, with live and archived webcast access available on its …

Levi & Korsinsky Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS

Levi & Korsinsky, LLP is reminding investors of Erasca, Inc. (NASDAQ: ERAS) about a pending class action lawsuit with a lead plaintiff deadline of August 10, 2026. The lawsuit alleges that Erasca made misleading statements regarding its drug ERAS-0015, particularly concerning its comparisons to …

Shareholders of Erasca, Inc. (ERAS): Protect Your Rights Before August 10, 2026 - Contact Levi & Korsinsky

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Erasca, Inc. (NASDAQ:ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made false statements and concealed that ERAS-0015's preclinical data …

Verastem (VSTM) to Post Quarterly Earnings on Thursday

ERAS|Erasca Inc|Price:17.720|Chg%:-0.440

This article provides a detailed overview of Erasca Inc (ERAS) stock, including its current price of $17.72, a 2.42% daily decrease, and a market capitalization of $5.04 billion. It highlights significant year-to-date and 1-year price increases, analyst ratings showing a "Buy" consensus with a …

Peraso Inc (PRSO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Peraso Inc (PRSO), detailing its current price momentum score, support and resistance levels, and various technical indicators. The analysis shows PRSO is currently trading between a resistance level of $0.83 and a support level of $0.50. Technical …

VSTM|Verastem Inc|Price:6.013|Chg%:-0.217

This article provides a comprehensive stock analysis of Verastem Inc (VSTM) by TradingKey, highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The company's stock is rated "Buy" by multiple analysts with a target price …

Enterprise value to revenue forward of Erasca, Inc. – NASDAQ:ERAS

This article focuses on the enterprise value to revenue for Erasca, Inc. (NASDAQ: ERAS). It primarily presents the company's financial overview and market information from TradingView. The content is sparse, mainly providing navigation and legal information related to the financial data platform.

Erasca Inc (ERAS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Erasca Inc (ERAS), focusing on support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, and STOCH, along with their current values and directions, and examines different moving averages to assess potential buy …

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Verastem Oncology has dosed the first patient in its TARGET-D 203 Phase 2 clinical trial, evaluating the investigational oral KRAS G12D inhibitor VS-7375 for metastatic colorectal cancer (mCRC). This marks the initiation of treatment across all three of Verastem's registration-directed Phase 2 trials for …

ERASCA, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 10, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS) investors of the August 10, 2026 deadline involving a securities fraud class action lawsuit commenced against the …

Peraso, Inc. Revenue Breakdown – MUN:N6Z

Peraso, Inc. (MUN:N6Z) generated 10.38 million EUR in revenue last year. The majority of this revenue, 5.73 million EUR, came from its MillimeterWave Integrated Circuits segment. Geographically, Taiwan was the biggest contributor, accounting for 4.49 million EUR of the company's revenue.

PRSO|Peraso Inc|Price:0.665|Chg%:-0.028

This article provides a comprehensive stock analysis of Peraso Inc (PRSO) by TradingKey, highlighting its healthy fundamentals and good growth potential. The company's stock is considered fairly valued, with institutional ownership being very high and recent analyst ratings indicating a "Strong Buy." However, the …

ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Erasca, Inc. (NASDAQ:ERAS) and its officers. The lawsuit alleges that Erasca made false or misleading statements regarding ERAS-0015's preclinical data, specifically concerning improper comparisons and potential patent violations. Investors who purchased Erasca …

Verastem Inc (VSTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Verastem Inc (VSTM), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 28, 2026, VSTM has a price momentum score of 6.17 and is trading between a resistance level of …

Peraso Inc (PRSO) Institutional Confidence

This article provides details on the institutional confidence in Peraso Inc (PRSO), including its current stock performance and institutional shareholding data. It lists several institutional holders and their changes in shares held, such as Ionic Ventures LLC, McWalter (Ian), Brio Capital Management LLC, and …

Verastem’s VS-7375 trials now span pancreatic, colorectal and lung cancers

Verastem Oncology has dosed the first patient in its TARGET-D 203 Phase 2 trial for VS-7375, an oral KRAS G12D inhibitor, targeting metastatic colorectal cancer. This marks the initiation of treatment across all three of its TARGET-D registration-directed Phase 2 trials for VS-7375, which …

Kaplan Fox Encourages Investors of Erasca, Inc. (NASDAQ: ERAS) to Contact the Firm Before Lead Plaintiff Deadline on August 10, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made misleading statements regarding its drug ERAS-0015, specifically …

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. Lawsuit - ERAS

The Gross Law Firm is notifying shareholders of Erasca, Inc. (NASDAQ: ERAS) about a lead plaintiff deadline of August 10, 2026, in a class-action lawsuit. The lawsuit alleges that Erasca made materially false and misleading statements from January 14, 2025, to April 26, 2026, …

Jerash Holdings (US) Inc (JRSH) Valuation: PE, PB & Fair Value Analysis

This article provides an updated valuation analysis for Jerash Holdings (US) Inc (JRSH), noting its current valuation score is 8.54, placing it 17th in the Textiles & Apparel industry. The P/E ratio is 31.47, significantly below its recent high and above its recent low. …

Jerash Holdings (US), Inc. SEC Filing (Jul 28, 2026)

This article reports on an SEC filing (Form ARS) by Jerash Holdings (US), Inc. (JRSH) on July 28, 2026. The filing was accepted by the SEC EDGAR system at 08:03 AM UTC on that date. The article also provides links to view the PDF …

Kaplan Fox Urges Investors of Erasca, Inc. (ERAS) with Significant Losses to Seek a Leadership Role Before August 10, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made false or misleading statements regarding its drug …

Jerash Holdings (US) Inc (JRSH) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Jerash Holdings (US) Inc (JRSH), noting its current score of 4.25 and ranking within the Textiles & Apparel industry. It details the company's beta value of 1.09, indicating higher volatility compared to the S&P 500 index. The …

Verastem Inc (VSTM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Verastem Inc (VSTM), identifying its major institutional and individual holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings for key investors. The report also lists …

US Consumer Stocks Better Placed for Higher Import Tariffs

New US tariffs of 10% to 12.5% on imports are shifting the landscape for consumer stocks, favoring companies with domestic production or alternative supply chains. This article analyzes three US consumer goods stocks—Unifi (UFI), Amer Sports (AS), and Jerash Holdings (US) (JRSH)—that appear well-positioned …

ERASCA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), of the important August …

Merger Mania: DFNS, ANY, PRSO, MOBX, VIVK, Drive Momentum Across High-Growth Sectors

This article highlights companies experiencing momentum due to mergers, acquisitions, and strategic growth initiatives across high-growth sectors like electric vehicles, military defense, AI, and autonomous systems. T3 Defense Inc. (DFNS), Sphere 3D Corp. (ANY), Peraso Inc. (PRSO), Vivakor, Inc. (VIVK), and Mobix Labs, Inc. …

Erasca Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed profile of Erasca Inc (ERAS), a clinical-stage precision oncology company focusing on RAS/MAPK pathway-driven cancers. It outlines the company's business scope, pipeline including naporafenib (a pan-RAF inhibitor), key financial data, and a list of its executives and top shareholders. …

Peraso Inc (PRSO) Balance Sheet

This article presents the quarterly and annual balance sheets for Peraso Inc (PRSO), providing detailed financial data. It allows users to evaluate the company's financial health by analyzing fundamentals and calculating key ratios for liquidity, leverage, and return on equity. The content also addresses …